On June 29, Quantinuum declined 5.13% in regular trading, trading at approximately $71.55 per share, with turnover of $88.71 million. The stock had surged over 5% in pre-market trading before reversing sharply during the regular session.

On the news front, at least nine major Wall Street investment banks simultaneously initiated research coverage on Quantinuum on the same day, with the vast majority assigning positive ratings. JPMorgan initiated at Overweight with a $97 price target; BofA Securities and Needham both initiated at Buy with $100 targets; Rosenblatt initiated at Buy with the highest target of $155; UBS initiated at Buy with a $93 target; Jefferies, Cantor Fitzgerald, and Mizuho each initiated at Buy or equivalent with $90 targets; while Morgan Stanley was the sole neutral voice, initiating at Equalweight with a $78 target. Despite the overwhelmingly bullish consensus, the stock experienced a classic sell-the-news reversal, with the prior three trading sessions already having accumulated losses exceeding 10%. The company currently carries a negative price-to-earnings ratio with a market capitalization of approximately $19.7 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)